Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
- 4 May 2007
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 47 (2), 174-182
- https://doi.org/10.1016/j.jhep.2007.02.025
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletionBlood, 2005
- Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infectionHepatology, 2005
- Viral and Nonviral Uses of Imiquimod: A ReviewJournal of Cutaneous Medicine and Surgery, 2004
- Immunopharmacology of CpG Oligodeoxynucleotides and RibavirinAntimicrobial Agents and Chemotherapy, 2004
- Randomized, Single-Blind, Placebo-Controlled Studyof Topical Application of the Immune Response ModulatorResiquimod in HealthyAdultsAntimicrobial Agents and Chemotherapy, 2003
- HCV Persistence and Immune Evasion in the Absence of Memory T Cell HelpScience, 2003
- Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848Nature Immunology, 2002
- Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathwayNature Immunology, 2002
- Interferon-??-2b Plus RibavirinDrugs, 2002
- Noncytolytic Control of Viral Infections by the Innate and Adaptive ImmuneResponseAnnual Review of Immunology, 2001